The first humanitarian aid from Pleven is already on its way to the twin city of Nikolayev, expected to arrive tomorrow at noon.
The main donation consists of antiviral preparations, sleeping bags, external batteries for charging mobile phones, backpacks, lanterns – these were the requests of the local government in Nikolaev. The medicines were provided by Tchaikapharma High Quality Medicines through the Municipality of Pleven, the rest of the humanitarian aid was purchased from the financial donations of dozens of Pleven residents who supported the campaign.
2021 was a very successful year for the manufacturing facilities of Tchaikapharma High Quality Medicines in Plovdiv and Varna. Numerous improvements related to the modernization of the manufactiring process were introduced at the company’s plant in Plovdiv:
– a Production Permit was obtained for a new granulation room in the tablet manufacturing facility, doubling the capacity;
– additional warehouses for shaped parts were built;
– a capsule filling machine for solid capsules was purchased and installed;
– a Manufacturing Permit was obtained to include a new manufacturing activity – production of non-sterile products – hard capsules;
– a roller-compactor for dry granulation has been purchased and installed;
– new serialization equipment with Temper Evident module was purchased and installed on packaging line 4;
– a new high-performance liquid chromatography apparatus and a new stability monitoring chamber were purchased for the Quality Control Department.
In 2021, the manufacturing of sterile antibiotics from the group of cephalosporins, has increased manifold at the plant of Tchaikapharma in Varna.
The Company reports about growth in sales of antibiotics and respiratory drugs
Tchaikapharma High Quality Medicines Inc. reports revenue growth and profit more than doubling by the end of 2021. The company’s net profit at the end of the last quarter for 2021 amounted to BGN 1,667 million compared to BGN 604 thousand at the end of 2020, an increase of 176%.
The strongest growth in 2021 was reported in sales of antibiotics and respiratory medicines, given the prevalence of COVID-19, to BGN 7,325 million compared to BGN 4,42 million in the previous year, or by 65,72% (BGN 2,9 million). There was also growth in sales of the company’s drugs for the nervous system, as well as for the digestive system and metabolism, oncology and musculoskeletal system and connective tissue.
In the last year, Tchaikapharma’s shares rose by 9.5% and its market capitalisation reached BGN 1.1 billion.
The full article is available here in Bulgarian.
The newest medicinal product to receive a Marketing Authorization from the Bulgarian Drug Agency is:
TromBay 100 mg tablets (with active ingredient cilostazol).
Its actions are several and include dilating certain blood vessels and reducing the clotting activity (agglutination) of certain blood cells, called platelets, in blood vessels.
The medicinal product is prescribed for “intermittent claudication” – a cramp-like pain in the legs when walking and is caused by insufficient blood supply to the lower limbs. TromBay can increase the distance you can walk without pain as it improves blood circulation in the legs. TromBay is only recommended for patients whose symptoms have not improved enough after making lifestyle changes (such as quitting smoking and increasing exercise) or after other appropriate treatments. It is important that patients continue with the changes they have made to improve their lifestyle while taking TromBay.
The medicinal product is subject to prescription.
ATC code: B01AC23
SOFIX was one of the most successful stock indices in 2021. The indicator outlined a successful trading on the Bulgarian Stock Exchange for both investors and public companies. For the twelve months of last year, the “blue chip” index grew by 42.23% to 635.68 points, showed a study by the newspaper. “Banker”. The main index of the Bulgarian Stock Exchange – SOFIX, ends 2021 in second place in terms of growth in the region of Central and Eastern Europe. It was outpaced only by OMX Tallin in Estonia, but only by a small margin /with 48.92% growth/.
For the second year in a row, the shares of Tchaikapharma High Quality Medicines Inc continue to gain value, and the drug manufacturing company also welcomes 2022 as the company with the largest market capitalization on the BSE-Sofia.
The pharmaceutical company started the 2021 stock exchange year at a share price of BGN 13.50 per unit. And twelve months later, the generic drug manufacturer’s shares added another BGN 1.40 to their value. Thus, the market capitalization of Tchaikapharma at the end of December reached BGN 1 259 050 000.
Not only the sector in which the company operates – the production of medicines – it supplies both potent products to leading international companies and generic ones produced in its plants in Plovdiv and Varna, but also its business plans and financial results support this growth of the shares.
Expansion activities at the tablet manufacturing facility in Plovdiv continue. The new equipment, which is in a test period, has been installed and staff has been trained. The construction of the additional warehouses for format parts has been completed and the premises are ready for start-up by the end of the year. The production permit is to be changed. Tihomir Kamenov controls 95.43% of the voting shares of the company.
BSE competitors on the “market capitalization” indicator also increased their market valuation, but are still far behind.
Read the full article here in Bulgarian.